I-Chondroitin Sulfate

-Delile

• Kungenzeka kusebenze ...
• Ubufakazi obanele bokukala ukusebenza kwe ...
• Ukuqapha okukhethekile nezixwayiso:

I-Chondroitin sulphate iyikhemikhali evame ukutholakala kuqwanga oluzungeze amalunga omzimba. I-Chondroitin sulphate ivame ukwenziwa kusuka emithonjeni yezilwane, njengoshaka noqwanga lwezinkomo. Kungenziwa futhi ebhodini.

Eminye imikhiqizo ye-chondroitin sulfate ayifakwanga ilebula ngokunembile. Kwezinye izimo, inani le-chondroitin liye lahluka kusuka kokunye kuya ngaphezu kwe-100% yenani elishiwo kulebula lomkhiqizo. Futhi, eminye imikhiqizo iqukethe i-chondroitin ethathwe ezilwaneni eziningi ezahlukahlukene, noma lokhu kungashiwo njalo kwilebula.

I-chondroitin sulfate isetshenziselwa i-osteoarthritis kanye ne-cataract. Kuvame ukusetshenziselwa ukuhlanganiswa nezinye izithako, kufaka phakathi i-manganese ascorbate, i-hyaluronic acid, i-collagen peptides, noma i-glucosamine. I-Chondroitin sulphate nayo iyathathwa ngomlomo, ifakwe esikhunjeni, futhi inikezwe njengesibhamu kwezinye izimo eziningi, kepha abukho ubufakazi obuhle besayensi bokusekela lokhu kusetshenziswa.

Imibhalo Yemvelo Yemininingwane Ephelele ukukala ukusebenza ngokuncike ebufakazini besayensi ngokwesilinganiso esilandelayo: Okusebenzayo, Okungenzeka Kusebenze, Okungenzeka Kusebenze, Okungenzeka Kungasebenzi, Cishe Okungaphumeleli, Ukungasebenzi, Nobufakazi Obunganele Bokulinganisa.

Izilinganiso zokusebenza ze I-CHONDROITIN SULFATE zimi kanje:

Kungenzeka kusebenze ...

• Isifo senkwethu. Ucwaningo lukhombisa ukuthi ukujova ikhambi eliqukethe i-chondroitin sulfate ne-sodium hyaluronate esweni kuvikela iso ngesikhathi sokuhlinzwa kwe-cataract. Imikhiqizo eminingi ehlukene equkethe i-chondroitin sulfate ne-sodium hyaluronate ibuyekezwe yi-U.S. Food and Drug Administration (FDA) ukuze isetshenziswe ngesikhathi sokuhlinzwa kwe-cataract. Kodwa-ke, akucaci ukuthi ukufaka i-chondroitin sulfate kuzixazululo ze-sodium hyaluronate kusiza ukunciphisa ingcindezi ngaphakathi kweso ngemuva kokuhlinzwa kwe-cataract uma kuqhathaniswa nezinye izindlela zokwelapha ezifanayo. Olunye ucwaningo lwakuqala lukhombisa ukuthi isisombululo esithile samehlo esiqukethe i-chondroitin sulfate ne-hyaluronate (i-Viscoat, i-Alcon Laboratories) singanciphisa ingcindezi esweni futhi sithuthukise impilo yamehlo jikelele ngemuva kokukhishwa kwe-cataract. Kodwa-ke, amaconsi abukeka angcono kunamaconsi aqukethe i-hyaluronate yodwa noma elinye ikhemikhali elibizwa nge-hydroxypropylmethyl-cellulose. Umphumela wezixazululo eziqukethe i-chondroitin sulfate kuphela ekuhlinzweni kwe-cataract awaziwa.
• I-osteoarthritis. Ucwaningo lomtholampilo lukhombisa ukuthi ukuthatha i-chondroitin sulfate ngomlomo kuthuthukisa ubuhlungu nokusebenza kwabanye abantu abane-osteoarthritis lapho isetshenziswa izinyanga eziyisithupha. Kubonakala kusebenza kahle kubantu abanezinhlungu ezinzima futhi lapho kusetshenziselwa ukulungiselela ibanga lezokwelapha. Imikhiqizo ethile ekhombise ukusizakala ezigulini ezine-osteoarthritis zibandakanya iChondrosulf (IBSA Institut Biochimique SA), iChondrosan (Bioibérica, SA), neStructrum (Laboratoires Pierre Fabre). Kepha ukuphumula kobuhlungu kungenzeka kube kuncane kakhulu. Olunye ucwaningo lukhombisa ukuthi ukuthatha i-chondroitin sulfate kuze kube yiminyaka emibili kunganciphisa ukuqhubeka kwe-osteoarthritis.
  Olunye ucwaningo luhlolisise imiphumela ye-chondroitin sulphate lapho ithathwa ngomlomo ngokuhlanganiswa ne-glucosamine. Olunye ucwaningo lukhombisa ukuthi ukuthatha imikhiqizo ethile equkethe i-chondroitin sulfate ne-glucosamine kusiza ekunciphiseni izimpawu ze-osteoarthritis. Olunye ucwaningo alukhombisi nzuzo uma kusetshenziswa amalungiselelo angewona awokuhweba. Ukuthatha i-chondroitin sulfate kanye ne-glucosamine isikhathi eside kubonakala kunciphisa ukuqhubeka kwe-osteoarthritis.
  Kunobunye ubufakazi bokuthi ukhilimu wesikhumba oqukethe i-chondroitin sulfate ngokuhlanganiswa ne-glucosamine sulfate, u-shark cartilage, ne-camphor kunganciphisa izimpawu ze-osteoarthritis. Kodwa-ke, noma yikuphi ukukhululeka kwezimpawu kungenzeka kakhulu kungenxa yekhamphor hhayi ezinye izithako. Alukho ucwaningo olubonisa ukuthi i-chondroitin imuncwa ngesikhumba.
  

Ubufakazi obanele bokukala ukusebenza kwe ...

• Ubuhlungu obuhlangene obubangelwa yimithi ebizwa ngokuthi i-aromatase inhibitors (i-aromatase inhibitor-induced arthralgias). Ucwaningo lwakuqala luphakamisa ukuthi ukuthatha inhlanganisela ye-glucosamine sulfate ne-chondroitin sulphate ngemithamo emibili noma emithathu ehlukanisiwe nsuku zonke amasonto angama-24 kuthuthukisa ubuhlungu obuhlangene nezimpawu ezidalwa yimithi esetshenziselwa ukwelapha umdlavuza webele.
• Iso elomile. Ucwaningo lwakuqala lukhombisa ukuthi ukusebenzisa amaconsi e-chondroitin sulphate kunganciphisa amehlo omile. Olunye ucwaningo lukhombisa ukuthi ukusebenzisa amaconsi wamehlo aqukethe i-chondroitin sulfate ne-xanthan gum kungathuthukisa amehlo omile mayelana nokusebenzisa izinyembezi zokufakelwa. Kepha olunye ucwaningo lwakuqala alukhombisi nzuzo.
• Ubuhlungu bemisipha obubangelwa ukuzivocavoca umzimba. Ucwaningo lwakuqala lukhombisa ukuthi ukuthatha i-chondroitin sulfate nsuku zonke akwehlisi ukukhathazeka kwemisipha ngemuva kokuzivocavoca emadodeni.
• Ukuvuvukala (ukuvuvukala) kwesisu (i-gastritis). Ucwaningo lokuqala lubonisa ukuthi ukuphuza uketshezi oluthile oluqukethe i-chondroitin sulfate ne-hyaluronic acid kunganciphisa ubuhlungu besisu kubantu abane-gastritis.
• I-pain bladder syndrome (i-cystitis yangaphakathi). Olunye ucwaningo lubonisa ukuthi ukufaka uketshezi nge-chondroitin sulfate esinyeni kungathuthukisa izimpawu zesinye esibuhlungu. Kepha eziningi zalezi zifundo ziyikhwalithi ephansi. Ezinye izifundo ezisezingeni eliphakeme ziphakamisa ukuthi ukusebenzisa i-chondroitin sulfate ngaphakathi kwesinye akusizi. Olunye ucwaningo lwakuqala lukhombisa ukuthi ukuthatha umkhiqizo oqukethe i-chondroitin sulfate nezinye izithako ngomlomo kungathuthukisa isinye esibuhlungu. Kodwa akucaci ukuthi inzuzo ivela ku-chondroitin sulfate noma ezinye izithako.
• Isifo esithinta amathambo namalunga, imvamisa kubantu abanesifo selenium (isifo seKashin-Beck). Ucwaningo lwakuqala luphakamisa ukuthi i-chondroitin sulfate, noma ingenayo i-glucosamine hydrochloride, inganciphisa ubuhlungu kubantu abanesifo seKashin-Beck. Futhi, ukuthatha i-chondroitin sulfate nge-glucosamine sulphate kunganciphisa isikhala esihlangene esincishayo kubantu abanalesi sifo samathambo. Kodwa-ke, akucaci ukuthi ukuthatha i-chondroitin sulfate kukodwa kubambezela isikhala esihlangene ngokuncipha.
• Isifo senhliziyo. Olunye ucwaningo lwakuqala lukhombisa ukuthi ukuthatha i-chondroitin sulfate ngomlomo kungehlisa ingozi yokuhlaselwa yisifo senhliziyo okokuqala noma okuphindaphindayo.
• Isikhumba, isikhumba esilumayo (psoriasis). Ucwaningo lwakuqala luphakamisa ukuthi ukuthatha i-chondroitin sulfate izinyanga ezingama-2-3 kunciphisa ubuhlungu futhi kuthuthukise izimo zesikhumba kubantu abane-psoriasis. Kepha olunye ucwaningo lukhombisa ukuthi ukuthatha i-chondroitin sulfate (Condrosan, CS Bio-Active, Bioiberica S.A., Barcelona, ​​Spain) nsuku zonke izinyanga ezi-3 akubunciphisi ubunzima be-psoriasis kubantu abane-psoriasis kanye ne-knee osteoarthritis.
• Ukulahlekelwa kokulawulwa kwesinye (ukungahambisani nomchamo). Ucwaningo lwakuqala luphakamisa ukuthi ukufaka i-sodium chondroitin sulfate esinyeni ngokusebenzisa ipayipi lomchamo kuthuthukisa izinga lempilo kubantu abanesinye esisebenza ngokweqile.
• Ukutheleleka kwezinso, isinye, noma i-urethra (izifo ezithinta umchamo noma ama-UTIs). Ucwaningo lwakuqala lukhombisa ukuthi ukufaka isisombululo esine-chondroitin sulfate ne-hyaluronic acid esinyeni nge-catheter kunciphisa inani lama-UTIs kwabesifazane abanomlando wama-UTIs.
• Isikhumba esiguga.
• Isilungulela esiphikelelayo.
• Isifo senhliziyo.
• I-cholesterol ephezulu.
• Amathambo abuthakathaka futhi anamandla (i-osteoporosis).
• Isikhumba esishwabene.
• Ezinye izimo.

Kudingeka ubufakazi obuningi ukukala i-chondroitin sulfate yalokhu kusetshenziswa.

Ku-osteoarthritis, uqwanga emajoyini luyawohloka. Ukuthatha i-chondroitin sulfate, enye yamabhulokhi wokwakha uqwanga, kunganciphisa lokhu kuphuka.

Lapho ithathwa ngomlomo: I-chondroitin sulfate iyi CISHE UVIKILE. I-Chondroitin sulfate ithathwe ngomlomo ngokuphepha kuze kube yiminyaka eyi-6. Kungadala izinhlungu ezithile zesisu kanye nesicanucanu. Eminye imiphumela emibi ebikiwe ukuqunjelwa, uhudo, ukuqunjelwa, ikhanda elibuhlungu, amajwabu amehlo avuvukile, ukuvuvukala kwemilenze, ukulahleka kwezinwele, ukuqubuka kwesikhumba, nokushaya kwenhliziyo okungajwayelekile.

Lapho ibekwa esweni: I-chondroitin sulfate iyi CISHE UVIKILE lapho isetshenziswa njengesisombululo samehlo ngesikhathi sokuhlinzwa kwamehlo.

Lapho unikezwa njengesibhamu: I-chondroitin sulfate iyi OKUNGENZEKA UKUPHEPHA lapho ufakwa emsipheni njengesibhamu, isikhathi esifushane.

Kukhona ukukhathazeka okuthile mayelana nokuphepha kwe-chondroitin sulfate ngoba kuvela emithonjeni yezilwane. Abanye abantu bakhathazekile ngokuthi izindlela zokukhiqiza ezingaphephile zingaholela ekungcolisweni kwemikhiqizo ye-chondroitin enezicubu zezilwane ezinesifo, kufaka phakathi lezo ezingadlulisa i-bovine spongiform encephalopathy (mad cow disease). Kuze kube manje, ayikho imibiko yokuthi i-chondroitin ibangela izifo kubantu, futhi ingozi kucatshangwa ukuthi iphansi.

Eminye imikhiqizo ye-chondroitin iqukethe inani elingaphezulu lama-manganese. Buza uchwepheshe wakho wezokunakekelwa kwezempilo mayelana nemikhiqizo ethembekile.

Ukuqapha okukhethekile nezixwayiso:

Ukukhulelwa nokuncelisa ibele: Alukho ulwazi olwanele oluthembekile lokwazi ukuthi ngabe i-chondroitin sulfate iphephile yini ukusetshenziswa uma ukhulelwe noma uncelisa ibele. Hlala ohlangothini oluphephile futhi ugweme ukusetshenziswa.

Isifuba Somoya: Kukhona okunye ukukhathazeka ngokuthi i-chondroitin sulfate ingenza i-asthma ibe yimbi kakhulu. Uma une-asthma, sebenzisa i-chondroitin sulfate ngokuqapha.

Ukuphazamiseka kwegazi: Ngokombono, ukuphatha i-chondroitin sulfate kungakhuphula ingozi yokopha kubantu abanezinkinga zokunqanda igazi.

Umdlavuza wendlala yesinye: Ucwaningo lokuqala lubonisa ukuthi i-chondroitin ingadala ukusabalala noma ukuphindeka komdlavuza wendlala yabesilisa. Lo mphumela awukhonjiswanga ngezithako ze-chondroitin sulfate. Kodwa-ke, kuze kube yilapho kwaziwa okuningi, ungathathi i-chondroitin sulphate uma unomdlavuza wendlala yesinye noma usengozini enkulu yokuwukhulisa (unomfowenu noma ubaba onomdlavuza wendlala yesinye).

Maphakathi

Qaphela ngale nhlanganisela.

I-Warfarin (Coumadin)

I-Warfarin (i-Coumadin) isetshenziselwa ukunciphisa ukubamba kwegazi. Kunemibiko eminingana ekhombisa ukuthi ukuthatha i-chondroitin nge-glucosamine kwandisa umphumela we-warfarin (Coumadin) ekunqandeni igazi. Lokhu kungadala ukulimala nokopha okungaba kubi kakhulu. Ungathathi i-chondroitin uma uthatha i-warfarin (Coumadin).

Akukho ukuxhumana okwaziwayo ngamakhambi nezengezo.

Akukho ukuxhumana okwaziwayo nokudla.

Imithamo elandelayo ifundwe ocwaningweni lwesayensi:

NGOMLOMO:

• Okwe-osteoarthritis: Umthamo ojwayelekile we-chondroitin sulfate ngu-800-2000 mg othathwe njengomthamo owodwa noma ngemithamo emibili noma emithathu ehlukaniswe nsuku zonke kuze kube yiminyaka emithathu.

Kusetshenziswe esikhunjeni:

• Okwe-osteoarthritis: Ukhilimu oqukethe u-50 mg / gram we-chondroitin sulfate, 30 mg / gram we-glucosamine sulfate, 140 mg / gram we-shark cartilage, kanye no-32 mg / gram we-camphor usetshenzisiwe njengoba kudingeka kumajoyinti abuhlungu kuze kube amasonto ayi-8.

UKUFAKWA EMSANGWENI:

• Okwe-osteoarthritis: I-Chondroitin sulphate (iMatrix) ijojowe ezicutshini nsuku zonke noma kabili ngesonto izinyanga eziyisithupha.

SISETSHENZISWA ESELWENI:

• Ngamehlo: Amaconsi wamehlo ahlukahlukene aqukethe i-sodium hyaluronate ne-chondroitin sulfate (i-DisCoVisc, i-Alcon Laboratories; i-Viscoat, i-Alcon Laboratories; i-DuoVisc, i-Alcon Laboratories; i-Viscoat, i-Alcon Laboratories; i-Provisc, i-Alcon Laboratories) asetshenzisiwe ngesikhathi sokuhlinzwa kwe-cataract.

Calcium Chondroitin Sulfate, CDS, Chondroitin, Chondroitin Polysulfate, Chondroitin Polysulphate, Chondroitin Sulfate A, Chondroitin Sulfates, Chondroitin Sulfate B, Chondroitin Sulfate C, Chondroitin Sulphates, Chondroondin Sulphatine, Chondroitin Sulphatine, Chondroitin Sulfate , Chondroondtine 4-Sulfate, Chondroïtine 4- et 6- Sulfate, Condroitin, CPS, CS, CSA, CSC, GAG, Galactosaminoglucuronoglycan Sulfate, Chondroitin 4-Sulfate, Chondroitin 4- no-6-Sulfate, Poly- (1-> 3) -N-Aceltyl-2-Amino-2-Deoxy-3-O-Beta-D-Glucopyranurosyl-4- (noma 6-), Polysulfate de Chondroïtine, Sulfate de Chondroïtine, Sulfate de Galactosaminoglucuronoglycane, Sulfates de Chondroïtine Sulfatoatoine .

Ukuze ufunde kabanzi ngokuthi le ndatshana ibhalwe kanjani, sicela ubheke ifayela le- Imibhalo Yemvelo Yemininingwane Ephelele indlela.

1. UBruyere O, Honvo G, uVeronese N, et al. Isincomo esibuyekeziwe se-algorithm sokuphathwa kwamadolo i-osteoarthritis avela ku-European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Disease (ESCEO). I-Semin I-Arthritis Rheum. 2019 Disemba; 49: 337-50. Buka okungaqondakali.
2. INavarro SL, Levy L, Curtis KR, Lampe JW, Hullar MAJ. Ukushintshashintsha kweGut Microbiota nguGlucosamine noChondroitin esivivinyweni esingahleliwe, esiphindwe kabili esimpumputhe esivivinyweni sabantu. Ama-microorganisms. 2019 Novemba 23; 7. pii: E610. Buka okungaqondakali.
3. URainaino OF, Finamore R, uStellavato A, et al. Izithako zokudla zase-European chondroitin sulfate kanye ne-glucosamine: Ukuhlolwa kwekhwalithi nokuhleleka okuhlelekile uma kuqhathaniswa nemithi yokwelapha. I-Carbohydr Polym. 2019 Okthoba 15; 222: 114984. Buka okungaqondakali.
4. UKolasinski SL, uNeogi T, uHochberg MC, et al. Umhlahlandlela we-2019 American College of Rheumatology / Arthritis Foundation wokuphathwa kwe-osteoarthritis yesandla, inqulu, nedolo. I-Arthritis Rheumatol. 2020 uFebhu; 72: 220-33. Buka okungaqondakali.
5. I-Savarino V, i-Pace F2, i-Scarpignato C; Iqembu le-Esoxx Study. Isivivinyo somtholampilo esingahleliwe: ukuvikelwa kwe-mucosal kuhlanganiswe nokucindezelwa kwe-asidi ekwelapheni isifo se-reflux esingagugisi - ukusebenza kwe-Esoxx, ukwakheka kwe-hio- hyaluronic acid-chondroitin sulphate based bioadhesive. I-Aliment Pharmacol Ther. 2017; 45: 631-642. Buka okungaqondakali.
6. UGoddard JC, uJanssen DAW. I-intravesical hyaluronic acid ne-chondroitin sulfate yokuthola izifo eziphindaphindayo zomgudu womchamo: ukubuyekezwa okuhlelekile nokuhlaziywa kwemeta. I-Int Urogynecol J. 2018 Jul; 29: 933-942. I-Epub 2017 Nov 27. Isibuyekezo. Buka okungaqondakali.
7. U-Iannitti T, uMorales-Medina JC, uMerighi A, et al. Idivayisi yezokwelapha esetshenziswa i-hyaluronic acid- ne-chondroitin sulfate ithuthukisa ubuhlungu besisu, ukungakhululeki, nezici ze-endoscopic. Ukususwa Kwezidakamizwa Kutolika. 2018 Okthoba; 8: 994-999. Buka okungaqondakali.
8. UTsuruta A, uHoriike T, uYoshimura M, uNagaoka I. Ukuhlolwa komphumela wokuphathwa kwe-glucosamine equkethe isengezo kuma-biomarkers we-cartilage metabolism kubadlali bebhola: Isifundo esilawulwa ngokungahleliwe se-placebo blind blind. I-Mol Med Rep. 2018 Okthoba; 18: 3941-3948. I-Epub 2018 Aug 17. Buka okungaqondakali.
9. I-Simental-Mendía M, Sánchez-García A, Vilchez-Cavazos F, Acosta-Olivo CA, Peña-Martínez VM, Simental-Mendía LE. Umphumela we-glucosamine ne-chondroitin sulphate ku-osteoarthritis ephawulekayo: ukubuyekezwa okuhlelekile nokuhlaziywa kwemeta kwezilingo ezilawulwa ngokungahleliwe ze-placebo. I-Rheumatol Int. 2018 Aug; 38: 1413-1428. I-Epub 2018 Jun 11. Ukubuyekeza. Buka okungaqondakali.
10. U-Ogata T, u-Ideno Y, u-Akai M, et al. Imiphumela ye-glucosamine ezigulini ezine-osteoarthritis yamadolo: ukubuyekezwa okuhlelekile nokuhlaziywa kwemeta. Umtholampilo Rheumatol. 2018 Septhemba; 37: 2479-2487. I-Epub 2018 Apr 30. Buka okungaqondakali.
11. I-Pyo JS, i-Cho WJ. Ukubuyekezwa okuhlelekile kanye nokuhlaziywa kwe-Meta-Analysis ye-Intravesical Hyaluronic Acid kanye ne-Hyaluronic Acid / Chondroitin Sulfate Instillation ye-Interstitial Cystitis / Painful Bladder Syndrome. Iseli Physiol Biochem. 2016; 39: 1618-25. Buka okungaqondakali.
12. I-Lopez HL, iZiegenfuss TN, iPark J. Ukuhlolwa Kwemiphumela ye-BioCell Collagen, i-Novel Cartilage Extract, kwi-Connective Tissue Support kanye ne-Recovery Functional kusuka ku-Exercise. I-Integr Med (Encinitas). 2015; 14: 30-8. Buka okungaqondakali.
13. UPérez-Balbuena AL, u-Ochoa-Tabares JC, uBelalcazar-Rey S, et al. Ukusebenza kwenhlanganisela engaguquki ye-0.09% xanthan gum / 0.1% chondroitin sulphate preservative free vs polyethylene glycol / propylene glycol ezifundweni ezinesifo samehlo esomile: isilingo esilawulwa ngokungahleliwe esilawulwa ngokungahleliwe. I-BMC Ophthalmol. 2016 Septhemba; 16: 164.Buka okungaqondakali.
14. UZeng C, Wei J, Li H, et al. Ukusebenza nokuphepha kweGlucosamine, chondroitin, okubili kuhlangene, noma i-celecoxib ekwelapheni i-osteoarthritis yamadolo. ISci Rep. 2015; 5: 16827. Buka okungaqondakali.
15. URoman-Blas JA, uCastañeda S, uSánchez-Pernaute O, et al. Ukwelashwa Okuhlanganisiwe Ne-Chondroitin Sulfate ne-Glucosamine Sulfate Show Akukhombisi Ukuphakama Kwe-Placebo Yokunciphisa Ubuhlungu Obusebenzayo Nokukhubazeka Okusebenzayo Ezigulini Ezine-Knee Osteoarthritis: I-Multicenter Yezinyanga Eziyisithupha, Engahleliwe, Eyimpumputhe, Isivivinyo Somtholampilo Esilawulwa Nge-Placebo. I-Arthritis Rheumatol. U-2017; 69: 77-85. Buka okungaqondakali.
16. UPelletier JP, uRaynauld JP, uBeaulieu AD, et al. Ukusebenza kweChondroitin sulphate kuqhathaniswa ne-celecoxib ekuguqulweni kwesakhiwo se-osteoarthritis kusetshenziswa imaging resonance imaging: isifundo seminyaka emibili sokuhlola izinto eziningi. I-Arthritis Res Ther. 2016; 18: 256. Buka okungaqondakali.
17. USingh JA, uNoorbaloochi S, uMacDonald R, uMaxwell LJ. I-Chondroitin ye-osteoarthritis. ICochrane Database Syst Rev. 2015 Jan 28; 1: CD005614. Buka okungaqondakali.
18. UBruyère O, Cooper C, uPelletier JP, et al. Isitatimende sokuvumelana nge-European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm yokuphathwa kwamadolo i-osteoarthritis-Kusuka emithini esuselwe ebufakazini iye esimeni sempilo yangempela. I-Semin I-Arthritis Rheum. 2016; 45 (4 Suppl): S3-11. Buka okungaqondakali.
19. Reginster JY, Dudler J, Blicharski T, Pavelka K. Pharmaceutical-grade Chondroitin sulfate iyasebenza njenge-celecoxib futhi iphakeme kune-placebo ku-symptomatic knee osteoarthritis: i-ChONdroitin iqhathaniswa ne-CElecoxib ne-Placebo Trial (CONCEPT). U-Ann Rheum Dis. 2017 uMeyi 22. pii: annrheumdis-2016-210860. Buka okungaqondakali.
20. IVolpi N. Ikhwalithi yamalungiselelo e-chondroitin sulfate ahlukile maqondana nomsebenzi wabo wokwelapha. UJ Pharm Pharmacol 2009; 61: 1271-80. Buka okungaqondakali.
21. I-Lauder RM. I-Chondroitin sulphate: i-molecule eyinkimbinkimbi enemithelela engaba khona ezinhlotsheni eziningi zezinto eziphilayo. Qedelela iTher Med 2009; 17: 56-62. Buka okungaqondakali.
22. UBarnhill JG, Fye CL, Williams DW, Reda DJ, Harris CL, Clegg DO. Ukukhethwa komkhiqizo weChondroitin wesilingo sokungenelela kwe-glucosamine / chondroitin arthritis. UJ Am Pharm Assoc 2006; 46: 14-24. Buka okungaqondakali.
23. UZegels B, uCrozes P, u-Uebelhart D, uBruyère O, u-Reginster JY. Ukulingana komthamo owodwa (1200 mg) uma kuqhathaniswa nomthamo wosuku kathathu (400 mg) we-chondroitin 4 & 6 sulfate ezigulini ezine-osteoarthritis yamadolo. Imiphumela yesifundo esilawulwa ngokungahleliwe esiphindwe kabili se-placebo. I-Osteoarthritis Cartilage 2013; 21: 22-7. Buka okungaqondakali.
24. I-Vigan M. Allergic contact dermatitis ebangelwa i-sodium chondroitin sulfate equkethwe ukhilimu wezimonyo. Xhumana ne-Dermatitis 2014; 70: 383-4. Buka okungaqondakali.
25. UTorella M, Schettino MT, uSalvatore S, uSerati M, uDe Franciscis P, uColacurci N. Ukwelashwa kwe-intravesical ku-cystitis ephindaphindwayo: isipiliyoni sezikhungo eziningi. J Ukuthelela uChemother 2013; 19: 920-5. Buka okungaqondakali.
26. Schneider H, Maheu E, Cucherat M. Umphumela wokuguqula uphawu lwe-chondroitin sulphate emadolweni i-osteoarthritis: ukuhlaziywa kwe-meta-ukuhlaziywa kwezilingo ezilawulwa ngokungahleliwe ezenziwa nge-structum (®). Vula iRheumatol J. 2012; 6: 183-9. Buka okungaqondakali.
27. I-Palmieri B, i-Merighi A, i-Corbascio D, i-Rottigni V, i-Fistetto G, i-Esposito A. Inhlanganisela engaguquki yokwenziwa ngomlomo kwe-hyaluronic acid kanye ne-chondroitin-sulphate ukwakheka komlomo esifundweni esilawulwa kabili esingahleliwe, sokulawulwa kwe-placebo ekwelapheni izimpawu kwiziguli ezine-gastroesophageal engagugi. i-reflux. I-Eur Rev Med Pharmacol Sci 2013; 17: 3272-8. Buka okungaqondakali.
28. ILlamas-Moreno JF, iBaiza-Durán LM, iSaucedo-Rodríguez LR, i-Alaníz-De la O JF. Ukusebenza nokuphepha kwe-chondroitin sulfate / xanthan gum kuqhathaniswa ne-polyethylene glycol / propylene glycol / hydroxypropyl guar ezigulini ezineso elomile. Umtholampilo Ophthalmol 2013; 7: 995-9. Buka okungaqondakali.
29. UDe Vita D, u-Antell H, uGiordano S. Ukusebenza kahle kwe-intravesical hyaluronic acid nge noma ngaphandle kwe-chondroitin sulfate yama-bacterial cystitis aphindaphindiwe kwabesifazane abadala: ukuhlaziywa kwe-meta. I-Int Urogynecol J 2013; 24: 545-52. Buka okungaqondakali.
30. UGreenlee H, uCrew KD, Shao T, Kranwinkel G, Kalinsky K, Maurer M, Brafman L, Insel B, Tsai WY, Hershman DL. Isigaba II sokufunda nge-glucosamine ne-chondroitin ku-aromatase inhibitor ehambisana nezimpawu ezihlangene zabesifazane abanomdlavuza webele. Ukusekela Umdlavuza Wokunakekela 2013; 21: 1077-87. Buka okungaqondakali.
31. UFransen M, Agaliotis M, Nairn L, Votrubec M, Bridgett L, Su S, Jan S, Mashi L, Edmonds J, Norton R, Woodward M, Usuku R; ILEGS ifunda iqembu elibambisanayo. I-Glucosamine ne-chondroitin yamadolo i-osteoarthritis: isilingo somtholampilo esilawulwa nge-placebo esilawulwa kabili esingahloliwe semithi eyodwa kanye nenhlanganisela. U-Ann Rheum Dis 2015; 74: 851-8. Buka okungaqondakali.
32. I-Provenza JR, iShinjo SK, iSilva JM, iPeron CR, iRocha FA. I-glucosamine ehlanganisiwe ne-chondroitin sulfate, kanye noma kathathu nsuku zonke, ihlinzeka nge-analgesia efanelekile emtholampilo ku-knee osteoarthritis. I-Clin Rheumatol 2015; 34: 1455-62. Bheka okungaqondakali.
33. von Felden J, Montani M, Kessebohm K, Stickel F. Ukulimala kwesibindi okubangelwa izidakamizwa okulingisa i-hepatitis ezenzakalelayo ngemuva kokudla izithako zokudla eziqukethe i-glucosamine ne-chondroitin sulfate. I-Int J Clin Pharmacol Ther 2013; 51: 219-23. Buka okungaqondakali.
34. UHochberg MC, uMartel-Pelletier J, uMonfort J, uMöller I, uCastillo JR, u-Arden N, uBerenbaum F, uBlanco FJ, uConaghan PG, uDoménech G, uHenrotin Y, uPap T, uRichette P, uSawitzke A, uDu Souich P, uPelletier JP ; egameni le-MOVES Investigation Group. I-chondroitin sulphate ne-glucosamine ehlanganisiwe ye-osteoarthritis yamadolo ebuhlungu: isilingo se-multicentre, randomized, blind-blind, non-inferiority versus celecoxib. U-Ann Rheum Dis 2016; 75: 37-44. Buka okungaqondakali.
35. UCerda C, Bruguera M, Parés A. Hepatotoxicity ehambisana ne-glucosamine ne-chondroitin sulfate ezigulini ezinesifo esingalapheki sesibindi. Umhlaba J Gastroenterol 2013; 19: 5381-4. Buka okungaqondakali.
36. UBray HG, uGregory JE, uStacey M. Chemistry Wezicubu. 1. I-Chondroitin evela ku-cartilage. I-Biochem J 1944; 38: 142-146.
37. I-FDA. Ukuvunyelwa kwangaphambili (PMA). Kutholakala ku: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=20196.
38. I-FDA inikezela ukuvunywa kwangaphambili kweViscoat. Amazinga okuphepha we-Biomed 1986; 16: 82.
39. UBlotman F noLoyau G. Isivivinyo somtholampilo nge-chondroitin sulfate ku-gonarthrosis [abstract]. Inqola ye-Osteoarthritis 1993; 1: 68.
40. I-Adebowale AO, iCox DS Liang Z Eddington ND. Ukuhlaziywa kokuqukethwe kwe-glucosamine ne-chondroitin sulphate kumikhiqizo emakethe kanye nokutholakala kwe-caco-2 kwezinto zokusetshenziswa ze-chondroitin sulfate. UJ Am Nutraceutical Assoc. 2000; 3: 37-44.
41. Pavelka futhi et al. Ucwaningo oluphindwe kabili, olunomthelela wethamo lomlomo cs 4 & 6 1200mg, 800mg, 200mg uqhathanisa ne-placebo ekwelapheni i-femorotibial osteoarthritis. I-Wular Rheumatol Liter 1998; 27 (suppl 2): ​​63.
42. UL'Hirondel JL. [Ucwaningo lwezimpumputhe oluphindwe kabili ngokusetshenziswa ngomlomo kwe-chondroitin sulphate kuqhathaniswa ne-placebo yokwelashwa kwe-tibio femoral gonarthrosis ezigulini eziyi-125]. I-Litera Rheumatologica 1992; 14: 77-84.
43. UFleisch, AM, uMerlin C, u-Imhoff A, no-al. Isifundo esilawulwa ngokungahleliwe, esingaboni kabili, esilawulwa nge-placebo ngomlomo we-chondroitin sulfate ezigulini ezine-osteoarthritis yamadolo. I-Osteoarthritis neCartilage 1997; 5: 70.
44. Uebelhart D kanye noChantraine A. I-Efficacite clinique du sulfate de chondroitine dans la gonarthrose: Etude randomisee en double-insu versus placebo [abstract]. UMfu Rhumatisme 1994; 10: 692.
45. UVerbruggen, G., Goemaere, S., noVeys, E. M. Chondroitin sulfate: S / DMOAD (isakhiwo / isifo esiguqula umuthi olwa ne-osteoarthritis) ekwelapheni i-OA yomunwe. I-Osteoarthritis Cartilage 1998; I-6 Suppl A: 37-38. Buka okungaqondakali.
46. UNakazawa, K., Murata, K., Izuka, K., no-Oshima, Y. Imiphumela yesikhashana ye-chondroitin sulfates A no-C ezifundweni ze-coronary atherosclerotic: Ngokuqondene nemisebenzi yayo elwa ne-thrombogenic. Inhliziyo J 1969; 10: 289-296. Buka okungaqondakali.
47. UNakazawa, K. noMurata, K. Ucwaningo lokuqhathanisa imiphumela yama-isonders e-chondroitin sulfate ezifundweni ze-atherosclerotic. ZFA. 1979; 34: 153-159. Buka okungaqondakali.
48. Thilo, G. [Ucwaningo lwamacala angama-35 e-arthrosis aphathwa nge-chondrotiine sulfuric acid (Author's transl)]. USchweizerische Rundschau fur Medizin Praxis 12-27-1977; 66: 1696-1699. Buka okungaqondakali.
49. I-Embriano, P. J. Ukucindezela kokusebenza ngemuva kwe-phacoemulsification: i-sodium hyaluronate vs. sodium chondroitin sulfate-sodium hyaluronate. U-Ann.Ophthalmol. 1989; 21: 85-88, 90. Buka okungaqondakali.
50. I-Railhac, JJ, Zaim, M., Saurel, AS, Vial, J., ne-Fournie, B. Umphumela wezinyanga eziyi-12 ukwelashwa nge-chondroitin sulfate kumthamo we-cartilage ezigulini zamadolo e-osteoarthritis: umshayeli olawulwa ngokungahleliwe, ongaboni kabili, olawulwa yi-placebo funda usebenzisa iMRI. Umtholampilo eRheumatol. 2012; 31: 1347-1357. Buka okungaqondakali.
51. UDe, Vita D. noGiordano, S. Ukusebenza kwe-intravesical hyaluronic acid / chondroitin sulfate ku-cystitis yebhaktheriya ephindaphindayo: isifundo esingahleliwe. Int .Urogynecol.J. 2012; 23: 1707-1713. Buka okungaqondakali.
52. UNickel, JC, Hanno, P., Kumar, K., noThomas, H. Okwesibili kokuhlola okuningiliziwe, okungahleliwe, okuyimpumputhe, okuhlola kweqembu ngokufana nokusebenza nokuphepha kwe-intravesical sodium chondroitin sulfate uma kuqhathaniswa nokulawulwa kwezimoto okungasebenzi ezifundweni ezine-interstitial i-cystitis / bladder pain syndrome. I-Urology 2012; 79: 1220-1224. Buka okungaqondakali.
53. UYue, J., Yang, M., Yi, S., Dong, B., Li, W., Yang, Z., Lu, J., Zhang, R., no-Yong, J. Chondroitin sulfate kanye / noma i-glucosamine hydrochloride yesifo sikaKashin-Beck: isifundo esilawulwa yiqoqo elilawulwa ngokungahleliwe. I-Osteoarthritis.Cartilage. 2012; 20: 622-629. Buka okungaqondakali.
54. UKanzaki, N., Saito, K., Maeda, A., Kitagawa, Y., Kiso, Y., Watanabe, K., Tomonaga, A., Nagaoka, I., noJamaguchi, H. Umphumela wesengezo sokudla. equkethe i-glucosamine hydrochloride, i-chondroitin sulphate ne-quercetin glycosides ku-osteoarthritis enophawu: isifundo esilawulwa ngokungahleliwe, esiyimpumputhe, esilawulwa yi-placebo. J.Sci.Izolimo Zokudla. 3-15-2012; 92: 862-869. Buka okungaqondakali.
55. UWildi, LM, Raynauld, JP, Martel-Pelletier, J., Beaulieu, A., Bessette, L., Morin, F., Abram, F., Dorais, M., noPelletier, JP Chondroitin sulphate kunciphisa bobabili uqwanga ukulahleka kanye nomnkantsha wamathambo ezigulini zamadolo e-osteoarthritis eziqala ezinyangeni eziyisithupha ngemuva kokuqala ukwelashwa: isifundo esilawulwa ngokungahleliwe, esimpumputhe, esilawulwa nge-placebo sisebenzisa iMRI. UMnu. Ann. 2011; 70: 982-989. Buka okungaqondakali.
56. UDamiano, R., Quarto, G., Bava, I., Ucciero, G., De, Domenico R., Palumbo, MI, no-Autorino, R. Ukuvimbela izifo eziphindaphindayo zomgudu womchamo ngokuphathwa kwe-hyaluronic acid ne-chondroitin sulphate : isilingo esilawulwa ngokungahleliwe se-placebo. Eur.Urol. 2011; 59: 645-651. Buka okungaqondakali.
57. UZhou, Q., Chen, H., Qu, M., Wang, Q., Yang, L., noXie, L. Ukwakhiwa kwemodeli yenoveli ex vivo yokunamathela kwesikhunta se-corneal. I-Graefes Arch.Clin.Exp.Ophthalmol. 2011; 249: 693-700. Buka okungaqondakali.
58. Liesegang, T. J. Viscoelastic izinto ku-ophthalmology. Ukusinda. Ophthalmol. 1990; 34: 268-293. Buka okungaqondakali.
59. UFurer, V., Wieczorek, R. L., noPillinger, M. H. Bilateral pinna chondritis elandelwa ukuqalwa kokungezelelwa kwe-glucosamine chondroitin. Scand.J.Rheumatol. 2011; 40: 241-243. Buka okungaqondakali.
60. U-Chen, W. C., Yao, C. L., Chu, I. M., no-Wei, Y. H. Qhathanisa imiphumela ye-chondrogenesis ngesiko lamangqamuzana ama-mesenchymal stem cell nezinhlobo ezahlukahlukene ze-chondroitin sulfate C. J. Biosci.Bioeng. 2011; 111: 226-231. Buka okungaqondakali.
61. UKato, D., Era, S., Watanabe, I., Arihara, M., Sugiura, N., Kimata, K., Suzuki, Y., Morita, K., Hidari, KI, noSuzuki, T. Antiviral. umsebenzi we-chondroitin sulphate E oqonde amaprotheni emvilophu yegciwane lodenga. Amagciwane Res. 2010; 88: 236-243. Buka okungaqondakali.
62. UWandel, S., Juni, P., Tendal, B., Nuesch, E., Villiger, PM, Welton, NJ, Reichenbach, S., noTrelle, S. Imiphumela ye-glucosamine, i-chondroitin, noma i-placebo ezigulini ezine-osteoarthritis. okhalweni noma idolo: ukuhlaziywa kwe-meta-analysis. BMJ 2010; 341: c4675. Buka okungaqondakali.
63. URentsch, C., Rentsch, B., Breier, A., Spekl, K., Jung, R., Manthey, S., Scharnweber, D., Zwipp, H., noBiewener, A. Ithambo elide libucayi- ukukhubazeka kosayizi okuphathwe ngezikulufu ezisebenza ngezicubu ezenziwe nge-polycaprolactone-co-lactide scaffolds: isifundo somshayeli kumagundane. UJ. Kuthunyelwe.Mater.Res. A 12-1-2010; 95: 964-972. Buka okungaqondakali.
64. U-Im, A. R., Park, Y., noKim, Y. S. Ukuhlukaniswa nokuhlukaniswa kwama-chondroitin sulfates avela ku-sturgeon (Acipenser sinensis) nemiphumela yawo ekukhuleni kwama-fibroblasts. Biol.Pharm.Inkunzi. 2010; 33: 1268-1273. Buka okungaqondakali.
65. USawitzke, AD, Shi, H., Finco, MF, Dunlop, DD, Harris, CL, Singer, NG, Bradley, JD, Silver, D., Jackson, CG, Lane, NE, Oddis, CV, Wolfe, F. , Lisse, J., Furst, DE, Bingham, CO, Reda, DJ, Moskowitz, RW, Williams, HJ, noClegg, DO Clinical efficacy and safety of glucosamine, chondroitin sulphate, inhlanganisela yabo, i-celecoxib noma i-placebo ethathwe ukwelapha i-osteoarthritis wamadolo: imiphumela yeminyaka emi-2 evela ku-GAIT. UMnu. Ann. 2010; 69: 1459-1464. Buka okungaqondakali.
66. I-Nickel, i-JC, i-Egerdie, i-RB, i-Steinhoff, i-G, i-Palmer, i-B, ne-Hanno, i-P.I-multicenter, i-randomized, blind-blind, ukuhlolwa kweqembu lokuhlola ukusebenza nokusebenza nokuphepha kwe-intravesical sodium chondroitin sulphate kuqhathaniswa nokulawulwa kwezimoto ku iziguli ezine-cystitis / isifo esibuhlungu sesinye. I-Urology 2010; 76: 804-809. Buka okungaqondakali.
67. UMoller, I., Perez, M., Monfort, J., Benito, P., Cuevas, J., Perna, C., Domenech, G., Herrero, M., Montell, E., noVerges, uJ. Ukusebenza kwe-chondroitin sulphate ezigulini ezine-concomitant knee osteoarthritis kanye ne-psoriasis: isifundo esilawulwa ngokungahleliwe, esingaboni kabili, esilawulwa yi-placebo. I-Osteoarthritis.Cartilage. 2010; 18 Isengezo 1: S32-S40. Buka okungaqondakali.
68. U-Egea, J., Garcia, A. G., Verges, J., Montell, E., noLopez, M. G. Antioxidant, izenzo zokulwa nokuvuvukala kanye ne-neuroprotective ye-chondroitin sulfate nama-proteoglycans. I-Osteoarthritis.Cartilage. 2010; 18 Isengezo 1: S24-S27. Buka okungaqondakali.
69. I-Hochberg, M. C. Imiphumela yokuguqula ukwakheka kwe-chondroitin sulphate emadolweni i-osteoarthritis: ukuhlaziywa kwemeta okubuyekeziwe kokuhlolwa okulawulwa nge-placebo okungahleliwe kwesikhathi seminyaka engu-2. I-Osteoarthritis.Cartilage. 2010; 18 Isengezo 1: S28-S31. Buka okungaqondakali.
70. Imada, K., Oka, H., Kawasaki, D., Miura, N., Sato, T., no-Ito, A. Izindlela zokulwa ne-arthritic ze-chondroitin sulfate yemvelo kuma-chondrocyte angama-articular nama-synovial fibroblasts. Biol.Pharm Bull. 2010; 33: 410-414. Buka okungaqondakali.
71. UPavelka, K., Coste, P., Geher, P., noKrejci, G. Ukusebenza nokuphepha kwe-piascledine 300 kuqhathaniswa ne-chondroitin sulfate ekwelashweni kwezinyanga eziyi-6 kanye nokubhekwa kwezinyanga ezimbili ezigulini ezine-osteoarthritis yamadolo. Umtholampilo eRheumatol. 2010; 29: 659-670. Buka okungaqondakali.
72. UTat, S. K., Pelletier, J. P., Mineau, F., Duval, N., noMartel-Pelletier, J. Imiphumela eguquguqukayo yezinhlanganisela ezi-3 ezahlukahlukene ze-chondroitin sulphate kuma-osteoarthritic cartilage / chondrocyte: ukubaluleka kwenhlanzeko nenqubo yokukhiqiza. UJ. Rheumatol. 2010; 37: 656-664. Buka okungaqondakali.
73. Lane, S. S., Naylor, D. W., Kullerstrand, L. J., Knauth, K., noLindstrom, R. L. Ukuqhathanisa okulindelekile kwemiphumela ye-Occucoat, Viscoat, ne-Healon ekucindezelekeni kwe-intraocular kanye ne-endothelial cell cell. J Cataract Refract. Ukuhlinzwa. 1991; 17: 21-26. Buka okungaqondakali.
74. UJackson, CG, Plaas, AH, Sandy, JD, Hua, C., Kim-Rolands, S., Barnhill, JG, Harris, CL, noClegg, DO Ama-pharmacokinetics womuntu wokufaka ngomlomo i-glucosamine ne-chondroitin sulfate ethathwe ngokwahlukana noma ngokuhlangana. I-Osteoarthritis Cartilage 2010; 18: 297-302. Buka okungaqondakali.
75. UBlack, C., Clar, C., Henderson, R., MacEachern, C., McNamee, P., Quayyum, Z., Royle, P., noThomas, S. Ukusebenza kwemitholampilo ye-glucosamine kanye ne-chondroitin supplements ekunciphiseni noma ukuboshwa kokuqhubeka kwe-osteoarthritis yamadolo: ukubuyekezwa okuhlelekile nokuhlolwa kwezomnotho. I-Health Technol. Ukuhlolwa. 2009; 13: 1-148. Buka okungaqondakali.
76. I-Sasisekharan, R. ne-Shriver, Z. Kusuka enkingeni kuya ethubeni: umbono ngenkinga ye-heparin. Ukuhlanya. U-2009; 102: 854-858. Buka okungaqondakali.
77. ICrowley, DC, Lau, FC, Sharma, P., Evans, M., Guthrie, N., Bagchi, M., Bagchi, D., Dey, DK, noRaychaudhuri, ukuphepha kwe-SP nokusebenza kohlobo lwe-collagen yohlobo olungafakwanga ukwelashwa kwe-osteoarthritis yamadolo: isilingo somtholampilo. Int.J.Med.Sci. U-2009; 6: 312-321. Buka okungaqondakali.
78. URainsford, K. D. Ukubaluleka kokuqanjwa kwemithi nobufakazi obuvela ezivivinyweni zokwelashwa kanye nezifundo zemithi ekutholeni ukusebenza kahle kwe-chondroitin sulphate namanye ama-glycosaminoglycans: a critique. J.Pharm.Pharmacol. U-2009; 61: 1263-1270. Buka okungaqondakali.
79. Hauser, P. J., Buethe, D. A., Califano, J., Sofinowski, T. M., Culkin, D. J., noHurst, R. E. Ukubuyisela umsebenzi wokuvimbela esinyeni esonakaliswe i-asidi yi-intravesical chondroitin sulfate. J.Urol. 2009; 182: 2477-2482. Buka okungaqondakali.
80. UKubo, M., Ando, ​​K., Mimura, T., Matsusue, Y., noMori, K. Chondroitin sulfate ekwelapheni i-hip ne-knee osteoarthritis: isimo samanje nezindlela ezizayo. Impilo Sci. 9-23-2009; 85 (13-14): 477-483. Buka okungaqondakali.
81. U-Lee, Y. H., Woo, J. H., Choi, S. J., Ji, J. D., no-Song, G. G. Umphumela we-glucosamine noma i-chondroitin sulfate ekuqhubekeni kwe-osteoarthritis: ukuhlaziywa kwe-meta. IRheumatol Int 2010; 30: 357-363. Buka okungaqondakali.
82. du Souich, P., Garcia, A. G., Verges, J., noMontell, E. Imithelela yokuzivikela yokulwa nokuvuvukala kwe-chondroitin sulphate. J.Cell Mol.Med. 2009; 13 (8A): 1451-1463. Buka okungaqondakali.
83. UFthenou, E., Zong, F., Zafiropoulos, A., Dobra, K., Hjerpe, A., noTzanakakis, G. N. Chondroitin sulphate A ilawula ukunamathela kwamaseli we-fibrosarcoma, ukuhamba nokunyakaza nge-JNK kanye ne-tyrosine kinase signaling pathways. KuVivo 2009; 23: 69-76. Buka okungaqondakali.
84. UBhattacharyya, S., Solakyildirim, K., Zhang, Z., Chen, ML, Linhardt, RJ, noTobacman, i-JK Cell-bound IL-8 iyanda kumaseli we-bronchial epithelial ngemuva kwe-arylsulfatase B ethulisa ngenxa yokulandelwa nge-chondroitin-4- i-sulfate. Am. J. Ukuphefumula. Iseli Mol. Biol. 2010; 42: 51-61. Buka okungaqondakali.
85. Schulz, A., Vestweber, A. M., noDressler, D. [Isenzo sokulwa nokuvuvukala se-hyaluronic acid-chondroitin sulphate ukulungiselela imodeli ye-in vitro bladder]. U-Aktuelle Urol. U-2009; 40: 109-112. Buka okungaqondakali.
86. UDavid-Raoudi, M., Deschrevel, B., Leclercq, S., Galera, P., Boumediene, K., noPujol, uJP Chondroitin sulphate yandisa ukukhiqizwa kwe-hyaluronan ngama-synoviocyte womuntu ngokulawulwa okwehlukile kwama-hyaluronan synthases: Indima ye-p38 kanye I-Akt. I-Arthritis Rheum. 2009; 60: 760-770. Buka okungaqondakali.
87. Matsuno, H., Nakamura, H., Katayama, K., Hayashi, S., Kano, S., Yudoh, K., noKiso, Y. Imiphumela yokuphathwa ngomlomo kwe-glucosamine-chondroitin-quercetin glucoside ku-synovial izakhiwo eziwuketshezi ezigulini ezine-osteoarthritis kanye nesifo samathambo. I-Biosci.I-Biotechnol.Ibhayoloji. U-2009; 73: 288-292. Buka okungaqondakali.
88. UKahan, A., Uebelhart, D., De, Vathaire F., Delmas, P.D., noReginster, J. Y. Imiphumela yesikhathi eside yama-chondroitins 4 no-6 sulphate kuma-osteoarthritis emadolweni: ucwaningo lokuvikela ukuqhubekela phambili kwe-osteoarthritis, isivivinyo seminyaka emibili, esingahleliwe, esingaboni kahle, esilawulwa yi-placebo. I-Arthritis Rheum. U-2009; 60: 524-533. Buka okungaqondakali.
89. URovetta, G. Galactosaminoglycuronoglycan sulfate (matrix) ekwelashweni kwe-tibiofibular osteoarthritis yamadolo. Izidakamizwa Exp Clin Res 1991; 17: 53-57. Buka okungaqondakali.
90. U-Oliviero, U., Sorrentino, GP, De Paola, P., Tranfaglia, E., D'Alessandro, A., Carifi, S., Porfido, FA, Cerio, R., Grasso, AM, Policicchio, D., futhi. Imiphumela yokwelashwa nge-matrix kubantu asebekhulile abanokuwohloka okungapheli kwe-articular. Izidakamizwa Exp Clin Res 1991; 17: 45-51. Buka okungaqondakali.
91. Bruyere, O., Burlet, N., Delmas, P. D., Rizzoli, R., Cooper, C., noReginster, J. Y. Ukuhlolwa kwezidakamizwa ezisebenza ngesineke ku-osteoarthritis kusetshenziswa uhlelo lweGRADE. BMC.Musculoskelet.Ukuphazamiseka. 2008; 9: 165. Buka okungaqondakali.
92. I-Theoharides, T. C., Kempuraj, D., Vakali, S., ne-Sant, G. R. Ukwelashwa kwe-cystitis yesibindi / isifo esibuhlungu sesinye nge-CystoProtek - isithasiselo semvelo somenzeli womlomo omningi. Ingabe uJ Urol 2008; 15: 4410-4414. Buka okungaqondakali.
93. Hochberg, M. C., Zhan, M., naseLangenberg, P. Izinga lokwehla kobubanzi besikhala esihlanganyelwe ezigulini ezine-osteoarthritis yamadolo: ukubuyekezwa okuhlelekile nokuhlaziywa kwemeta kokuhlolwa okulawulwa ngokungahleliwe kwe-placebo kwe-chondroitin sulfate. I-Curr.Med.Res.Opin. 2008; 24: 3029-3035. Buka okungaqondakali.
94. USawitzke, AD, Shi, H., Finco, MF, Dunlop, DD, Bingham, CO, III, Harris, CL, Singer, NG, Bradley, JD, Silver, D., Jackson, CG, Lane, NE, Oddis, I-CV, Wolfe, F., Lisse, J., Furst, DE, Reda, DJ, Moskowitz, RW, Williams, HJ, noClegg, DO Umphumela we-glucosamine kanye / noma i-chondroitin sulfate ekuqhubekeni kwe-osteoarthritis yamadolo: umbiko kusuka esivivinyweni sokungenelela se-glucosamine / chondroitin arthritis. I-Arthritis Rheum. 2008; 58: 3183-3191. Buka okungaqondakali.
95. UNickel, JC, Egerdie, B., Downey, J., Singh, R., Skehan, A., Carr, L., no-Irvine-Bird, K. Ucwaningo lwangempela lwempilo yezindlela eziningi zokwelapha ukuhlola ukusebenza nokuphepha we-intravesical chondroitin sulphate ekwelapheni i-cystitis yangaphakathi. BJU.Int. U-2009; 103: 56-60. Buka okungaqondakali.
96. UNordling, J. no-van, u-Ophoven A. Intravesical glycosaminoglycan replenishment nge-chondroitin sulphate ezinhlotsheni ezingapheli ze-cystitis. Isivivinyo somtholampilo wezizwe eziningi, wezikhungo eziningi, ozoba ngumqaphi wokuhlola okwenzekayo. Arzneimittelforschung. 2008; 58: 328-335. Buka okungaqondakali.
97. I-Theocharis, D. A., Skandalis, S. S., Noulas, A. V., Papageorgakopoulou, N., Theocharis, A. D., kanye noKaramanos, N. K. Hyaluronan kanye ne-chondroitin sulfate proteoglycans enhlanganweni ye-supramolecular yomzimba wama-mammalian vitreous. Xhuma. Izicubu Res. 2008; 49: 124-128. Buka okungaqondakali.
98. UFosang, A. J. noLittle, C. B. Ukuqonda izidakamizwa: ama-aggrecanases njengezinhloso zokwelapha i-osteoarthritis. Nat.Clin.Pract.Rheumatol. 2008; 4: 420-427. Buka okungaqondakali.
99. UPraveen, M. R., Koul, A., Vasavada, A. R., Pandita, D., Dixit, N. V., noDahodwala, F. F. DisCoVisc kuqhathaniswa nenqubo yegobolondo elithambile besebenzisa iViscoat neProvisc ku-phacoemulsification: isilingo somtholampilo esingahleliwe. J.Cataract Refract. Ukuhlinzwa. 2008; 34: 1145-1151. Buka okungaqondakali.
100. I-Dudics, V., Kunstar, A., Kovacs, J., Lakatos, T., Geher, P., Gomor, B., Monostori, E., no-Uher, F. Amandla weChondrogenic wamaseli we-mesenchymal stem avela ezigulini ezine-rheumatoid. i-arthritis ne-osteoarthritis: izilinganiso ohlelweni lwe-microculture. Amaseli izicubu.Izinhlelo 2009; 189: 307-316. Buka okungaqondakali.
101. UPorru, D., Cervigni, M., Nasta, L., Natale, F., Lo, Voi R., Tinelli, C., Gardella, B., Anghileri, A., Spinillo, A., noRovereto, B. Imiphumela ye-endovesical hyaluronic acid / chondroitin sulfate ekwelapheni i-Interstitial Cystitis / Painful Bladder Syndrome. UMfu Clinical Trials 2008; 3: 126-129. Buka okungaqondakali.
102. UCervigni, M., Natale, F., Nasta, L., Padoa, A., Voi, R. L., noPorru, D. Ukwelashwa okuhlangene kwe-intravesical ne-hyaluronic acid ne-chondroitin ye-refractory pain bladder syndrome / cystitis yangaphakathi. Int.Urogynecol.J.Pelvic.Floor.Dysfunct. 2008; 19: 943-947. Buka okungaqondakali.
103. UZhang, W., Moskowitz, RW, Nuki, G., Abramson, S., Altman, RD, Arden, N., Bierma-Zeinstra, S., Brandt, KD, Croft, P., Doherty, M., Dougados , M., Hochberg, M., Hunter, DJ, Kwoh, K., Lohmander, LS, noTugwell, P. OARSI izincomo zokuphathwa kwe-hip ne-knee osteoarthritis, Ingxenye II: OARSI-based-based, expert consensus guidelines. I-Osteoarthritis.Cartilage. 2008; 16: 137-162. Buka okungaqondakali.
104. URainer, G., Stifter, E., Luksch, A., noMenapace, R. Ukuqhathaniswa komphumela weViscoat neDuoVisc ekucindezelweni kwangaphakathi kwe-intraocular ngemuva kokuhlinzwa okuncane kwe-cataract. J.Cataract Refract. Ukuhlinzwa. 2008; 34: 253-257. Buka okungaqondakali.
105. Laroche, L., Arrata, M., Brasseur, G., Lagoutte, F., Le Mer, Y., Lumbroso, P., Mercante, M., Normand, F., Rigal, D., Roncin, S. , futhi. [Ukwelashwa kwe-eye eye syndrome nge-lacrimal gel: isifundo esingahleliwe se-multicenter]. UJ Fr. Ophtalmol. 1991; 14: 321-326. Buka okungaqondakali.
106. UConte, A., de Bernardi, M., Palmieri, L., Lualdi, P., Mautone, G., noRonca, G. Isiphetho semetabolism ye-chondroitin sulfate engaphandle kumuntu. Arzneimittelforschung. 1991; 41: 768-772. Buka okungaqondakali.
107. UBana, G., Jamard, B., Verrouil, E., noMazieres, B. Chondroitin sulfate ekuphathweni kwe-hip ne-knee osteoarthritis: ukubuka konke. U-Adv. Pharmacol. 2006; 53: 507-522. Buka okungaqondakali.
108. UMazieres, B., Hucher, M., Zaim, M., noGarnero, P. Umphumela we-chondroitin sulphate e-symptomatic knee osteoarthritis: isifundo esilawulwa nge-placebo. U-Ann Rheum Dis 2007; 66: 639-645. Buka okungaqondakali.
109. UBraun, W. A., Flynn, M. G., Armstrong, W., noJacks, D. D. Imiphumela ye-chondroitin sulphate supplementation kuma-indices wokulimala kwemisipha okubangelwa ukuvivinya ingalo okuqinile. J.Sports Med.Phys. Ukufaneleka 2005; 45: 553-560. Buka okungaqondakali.
110. UMichel, BA, Stucki, G., Frey, D., De, Vathaire F., Vignon, E., Bruehlmann, P., no-Uebelhart, D. Chondroitins 4 no-6 sulfate e-osteoarthritis yamadolo: okungahleliwe, okulawulwayo icala. I-Arthritis Rheum. 2005; 52: 779-786. Buka okungaqondakali.
111. URovetta, G., Monteforte, P., Molfetta, G., noBalestra, V. Ucwaningo lweminyaka emibili lwe-chondroitin sulfate ku-erosive osteoarthritis yezandla: ukusebenza kokuguguleka, ama-osteophytes, ubuhlungu nokungasebenzi kwesandla. Izidakamizwa Exp Clin Res 2004; 30: 11-16. Buka okungaqondakali.
112. Mathieu, P. [Ukuqhubekela phambili kwemisebe ye-osteoarthritis yangaphakathi ye-femoro-tibial ku-gonarthrosis. Umphumela wokuvikela i-chondroitin sulfates ACS4-ACS6]. Phakamisa iMed 9-14-2002; 31: 1386-1390. Buka okungaqondakali.
113. IVolpi, N. Ukutholakala kokutholakala ngomlomo kwe-chondroitin sulfate (Condrosulf) kanye nezakhi zayo kumavolontiya abesilisa anempilo. I-Osteoarthritis.Cartilage. 2002; 10: 768-777. Buka okungaqondakali.
114. URovetta, G., Monteforte, P., Molfetta, G., noBalestra, V. Chondroitin sulphate ekuqhumeni kwe-osteoarthritis yezandla. Int J Tissue React. 2002; 24: 29-32. Buka okungaqondakali.
115. USteinhoff, G., Ittah, B., noRowan, S. Ukusebenza kwe-chondroitin sulfate 0.2% ekwelapheni i-cystitis yangaphakathi. Ingabe uJ Urol 2002; 9: 1454-1458. Buka okungaqondakali.
116. O'Rourke, M. Ukunquma ukusebenza kwe-glucosamine ne-chondroitin ye-osteoarthritis. Umhlengikazi Pract 2001; 26: 44-52. Buka okungaqondakali.
117. [Imiphumela ezuzisayo yeChondrosulf 400 ebuhlungwini nasekusebenzeni kwe-articular ku-arthrosis: ukuhlaziywa kwe-meta]. Presse Med 2000; 29 (27 Suppl): 19-20. Buka okungaqondakali.
118. [Ucwaningo lwaseYurophu oluningi mayelana nokusebenza kwe-chondroitin sulfate ku-gonarthrosis: ukubukeka okusha kwemiphumela yamakhemikhali nemisebe ye-radiologic]. Presse Med 2000; 29 (27 Suppl): 15-18. Buka okungaqondakali.
119. U-Alekseeva, L. I., Benevolenskaia, L. I., Nasonov, E. L., Chichasova, N. V., noKariakin, A. N. [Structum (chondroitin sulfate) - i-ejenti entsha yokwelashwa kwe-osteoarthrosis]. I-Ter. 1999; 71: 51-53. Buka okungaqondakali.
120. I-Schwartz SR, iPark J. Ukufakwa kwe-BioCell Collagen, inoveli ekhishwe nge-hydrolyzed chicken sternal cartilage; ukukhushulwa kwegazi okuthuthukisiwe kanye nezimpawu zokuguga ebusweni ezincishisiwe. Ukuguga Kwe-Clin Interv. 2012; 7: 267-273. Buka okungaqondakali.
121. I-Schauss AG, i-Stenehjem J, i-Park J, i-Endres JR, i-Clewell A. Umphumela wenoveli yesisindo esincane se-hydrolyzed chicken sternal cartilage extract, i-BioCell Collagen, ekuthuthukiseni izimpawu ezihlobene ne-osteoarthritis: isilingo esilawulwa ngokungahleliwe, esingaboni kabili, esilawulwa yi-placebo. J Agric Ukudla Chem. 2012; 60: 4096-4101. Buka okungaqondakali.
122. UKalman DS, uSchwartz HI, uPachon J, uSheldon E, u-Almada AL. Isivivinyo somshayeli womtholampilo oyimpumputhe esingahleliwe esihlola ukuphepha nokusebenza kwe-hydrolyzed collagen type II kubantu abadala abane-osteoarthritis. I-FASEB Biology Yokuhlola 2004 Abstracts, Washington DC, Ephreli 17-21, 2004; I-A90.
123. I-Verges J, Montell E, Herrero M, et al. Ukuthuthuka komtholampilo kanye ne-histopathological ku-psoriasis ngomlomo we-chondroitin sulfate: ukutholakala okunamandla. IDermatol Online J 2005; 11: 31. Buka okungaqondakali.
124. UBurke S, uSugar J, uFarber MD. Ukuqhathaniswa kwemiphumela yama-viscoelastic agents amabili, uHealon noViscoat ekucindezelweni kwangaphakathi kwe-intraocular ngemuva kokungena kwe-keratoplasty. Ukuhlinzwa Kwamehlo Ophthalmic 1990; 21: 821-6. Buka okungaqondakali.
125. UZhang YX, uDong W, uLiu H, et al. Imiphumela ye-chondroitin sulfate kanye ne-glucosamine ezigulini zabantu abadala ezinesifo seKashin-Beck. Umtholampilo Rheumatol 2010; 29: 357-62. Buka okungaqondakali.
126. IGauruder-Burmester A, uPopken G. Ukulandelela ezinyangeni ezingama-24 ngemuva kokwelashwa kwesinye esisebenza ngokweqile nge-0.2% sodium chondroitin sulfate. U-Aktuelle Urol 2009; 40: 355-9. Buka okungaqondakali.
127. Uebelhart D, Knussel O, Theiler R. Ukusebenza nokubekezeleleka komlomo we-avian chondroitin sulfate ku-knee osteoarthritis ebuhlungu [abstract]. USchweiz Med Wochenschr 1999; 129: 1174.
128. U-Leeb BF, uPetera P, uNeumann K. Imiphumela yocwaningo lwe-multicenter ku-chondroitin sulfate (Condrosulf) esetshenziswa ku-arthrosis yomunwe, idolo nejoyini. I-Wien Med Wochenschr 1996; 146: 609-14. Buka okungaqondakali.
129. UGabay C, uMedinger-Sadowski C, uGascon D, et al. Umphumela we-Sympomatic we-chondroitin 4 ne-chondroitin 6 sulfate esandleni se-osteoarthritis: isilingo somtholampilo esilawulwa ngokungahleliwe, esingaboni kabili, esilawulwa nge-placebo esikhungweni esisodwa. I-Arthritis Rheum 2011; 63: 3383-91. Buka okungaqondakali.
130. I-Yue QY, iStrandell J, iMyrberg O. Ukusetshenziswa okuhambisanayo kwe-glucosamine kungahle kube nomphumela we-warfarin. Isikhungo Sokuqapha i-Uppsala. Kutholakala ku: www.who-umc.org/graphics/9722.pdf (Kufinyelelwe ngomhla ka-28 Ephreli 2008).
131. UKnudsen J, uSokol GH. Ukusebenzisana okungenzeka kwe-glucosamine-warfarin okuholele ekukhuleni kwesilinganiso esijwayelekile somhlaba jikelele: Umbiko wecala nokubuyekezwa kwemibhalo kanye nedatha ye-MedWatch. I-Pharmacotherapy 2008; 28: 540-8. Buka okungaqondakali.
132. UReichenbach S, uSterchi R, uScherer M, et al. Ukuhlaziywa kwemeta: i-chondroitin ye-osteoarthritis yamadolo noma inqulu. U-Ann Intern Med 2007; 146: 580-90. Buka okungaqondakali.
133. UMessier SP, uMihalko S, uLoeser RF, et al. I-Glucosamine / chondroitin ehlanganiswe nokuvivinya umzimba ekwelapheni i-knee osteoarthritis: isifundo sokuqala. I-Osteoarthritis Cartilage 2007; 15: 1256-66. Buka okungaqondakali.
134. UKahan A. STOPP (STUDY on Osteoarthritis Progression Prevention): isivivinyo esisha seminyaka emibili nge-chondroitin 4 & 6 sulfate (CS). Kutholakala ku: www.ibsa-ch.com/eular_2006_amsterdam_vignon-2.pdf (Kufinyelelwe ngomhla ka-25 Ephreli 2007).
135. UHuang J, u-Olivenstein R, uThaha R, et al. Ukufakwa kwe-proteoglycan okuthuthukisiwe odongeni lwasemoyeni lwe-atthic asthmatics. Ngingu-J J Respir Crit Care Med 1999; 160: 725-9. Buka okungaqondakali.
136. UClegg DO, uReda DJ, uHarris CL, et al. I-Glucosamine, i-chondroitin sulfate, kanye nalokhu okubili kuhlangene i-osteoarthritis yamadolo ebuhlungu. N Engl J Med 2006; 354: 795-808. Buka okungaqondakali.
137. Uebelhart D, Malaise M, Marcolongo R, et al. Ukwelashwa okungapheli kwamadolo i-osteoarthritis nge-chondroitin sulfate yomlomo: Ucwaningo lonyaka owodwa, okungahleliwe, okuyimpumputhe, lokufunda okuningi kuqhathaniswa ne-placebo. I-Osteoarthritis Cartilage 2004; 12: 269-76. Buka okungaqondakali.
138. USakko AJ, uRicciardelli C, uMayne K, et al. Ukushintshashintsha kokunamathiselwe kweseli lomdlavuza wesibeletho kumatrix nge-versican. I-Cancer Res 2003; 63: 4786-91. Buka okungaqondakali.
139. URozenfeld V, uCrain JL, uCallahan AK. Ukwanda okungenzeka komphumela we-warfarin yi-glucosamine-chondroitin. NginguJ J Health Syst Pharm 2004; 61: 306-307. Buka okungaqondakali.
140. UDi Caro A, uPerola E, uBartolini B, et al. Izingxenyana ze-galactosaminoglycan sulphates ezinamakhemikhali ngokweqile zivimbela amagciwane amathathu amboziwe: uhlobo lwegciwane lesandulela ngculazi lomuntu 1, uhlobo lwegciwane le-herpes simplex no-cytomegalovirus womuntu. I-Antivir Chem Chemother 1999; 10: 33-8 .. Buka okungaqondakali.
141. UDanao-Camara T. Imiphumela engemihle yokwelashwa nge-glucosamine ne-chondroitin. I-Arthritis Rheum 2000; 43: 2853. Buka okungaqondakali.
142. UCohen M, uWolfe R, uMai T, uLewis D. Isivivinyo esilawulwa ngokungahleliwe, esiyimpumputhe kabili, se-placebo sokhilimu owenziwe ngezihloko oqukethe i-glucosamine sulfate, i-chondroitin sulfate, ne-camphor ye-osteoarthritis yamadolo. J Rheumatol 2003; 30: 523-8 .. Buka okungaqondakali.
143. UBaici A, Horler D, Moser B, et al. Ukuhlaziywa kwama-glycosaminoglycans ku-serum yomuntu ngemuva kokuphathwa ngomlomo kwe-chondroitin sulfate. Rheumatol Int 1992; 12: 81-8 .. Buka okungaqondakali.
144. URichy F, uBruyere O, u-Ethgen O, et al. Ukusebenza okuhlelekile nokwakheka kwe-glucosamine ne-chondroitin ku-knee osteoarthritis: ukuhlaziywa okuphelele kwe-meta. I-Arch Intern Med 2003; 163: 1514-22. Buka okungaqondakali.
145. UHenry-Launois B. Ukuhlolwa kokusetshenziswa komthelela wezezimali weChondrosulf 400 kwezokwelapha njengamanje. Ingxenye yenqubo yeProjectings of a Scientific Symposium ebibanjelwe eXIth EULAR Symposium: Izindlela ezintsha e-OA: IChondroitin sulfate (CS 4 & 6) hhayi nje ukwelashwa okuyisifo. UGeneva, ngo-1998.
146. I-Verbruggen G, iGoemaere S, i-Veys EM. Izinhlelo zokuhlola ukuqhubekela phambili kwe-osteoarthritis ehlangene yomunwe kanye nemiphumela yezifo ezishintsha izidakamizwa ze-osteoarthritis. Umtholampilo Rheumatol 2002; 21: 231-43. Buka okungaqondakali.
147. UTallia AF, uCardone DA. Ukukhuphuka kwesifuba somoya okuhambisana nesengezo se-glucosamine-chondroitin. J Am Board Fam Pract 2002; 15: 481-4 .. Buka okungaqondakali.
148. URicciardelli C, uQuinn DI, uRaymond WA, et al. Amazinga aphakeme we-peritumoral chondroitin sulfate abikezela isibikezelo esibi ezigulini ezelashwa yi-radical prostatectomy yomdlavuza wesibeletho sokuqala. ICancer Res 1999; 59: 2324-8. Buka okungaqondakali.
149. UYlisastigui L, Bakri Y, Amzazi S, et al. Ama-glycosaminoglycans ancibilikayo awenzi umsebenzi we-RANTES wokulwa namagciwane ekuthelelekeni kwama-macrophages ayinhloko ngohlobo lwegciwane lesandulela-ngculazi lomuntu 1. I-Virology 2000; 278: 412-22. Buka okungaqondakali.
150. I-Adebowale AO, iCox DS, uLiang Z, et al. Ukuhlaziywa kokuqukethwe kwe-glucosamine ne-chondroitin sulphate kumikhiqizo emakethwayo kanye nokutholakala kwe-Caco-2 kwezinto zokusetshenziswa ze-chondroitin sulfate. UJANA 2000; 3: 37-44.
151. ICao LC, iBoeve ER, de Bruijn WC, et al. Ama-Glycosaminoglycans kanye ne-semisynthetic sulfated polysaccharides: ukubuka konke kwesicelo sabo esingaba khona ekwelapheni iziguli ezine-urolithiasis. I-Urology 1997; 50: 173-83. Buka okungaqondakali.
152. UMorrison LM. Ukwelashwa kwesifo senhliziyo se-coronary arteriosclerotic nge-chondroitin sulfate-A: umbiko wokuqala. UJ Am Geriatr Soc 1968; 16: 779-85. Buka okungaqondakali.
153. UMorrison LM, Bajwa GS, Alfin-Slater RB, Ershoff BH. Ukuvimbela izilonda zemithambo yegazi yi-chondroitin sulfate A emthanjeni we-coronary kanye ne-aorta yamagundane abangelwa yi-hypervitaminosis D, ukudla okuqukethe i-cholesterol. I-Atherosclerosis 1972; 16: 105-18. Buka okungaqondakali.
154. UMazieres B, uCombe B, uPhan Van A, et al. I-Chondroitin sulphate e-osteoarthritis yamadolo: isifundo somtholampilo esingahle sibe khona, esiphindwe kabili, esilawulwa yi-placebo. UJ Rheumatol 2001; 28: 173-81. Buka okungaqondakali.
155. UDas A Jr, uHammad TA. Ukusebenza kwenhlanganisela ye-FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. I-Osteoarthritis Cartilage 2000; 8: 343-50. Buka okungaqondakali.
156. IBhodi Yezokudla Nezokudla, Isikhungo Sezokwelapha. Ukufakwa Kwezikhombo Zezokudla ku-Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, neZinc. Washington, DC: National Academy Press, 2002. Itholakala ku: www.nap.edu/books/0309072794/html/.
157. IPipitone VR. I-Chondroprotection nge-chondroitin sulfate. Izidakamizwa Exp Clin Res 1991; 17: 3-7. Buka okungaqondakali.
158. Leffler CT, Philippi AF, Leffler SG, et al. I-Glucosamine, i-chondroitin, ne-manganese ascorbate yesifo esihlanganayo esiwohlokayo emadolweni noma emuva okuphansi: isifundo esilawulwa ngokungahleliwe, esiyimpumputhe, esilawulwa yi-placebo. IMil Med 1999; 164: 85-91. Buka okungaqondakali.
159. USilvestro L, uLanzarotti E, uMarchi E, et al. I-pharmacokinetics yabantu yama-glycosaminoglycans esebenzisa izinto ezinelebula ze-deuterium nezingafakwanga ilebula: ubufakazi bokumunzwa ngomlomo. Isemina I-Thromb Hemost 1994; 20: 281-92. Buka okungaqondakali.
160. IConte A, Volpi N, Palmieri L, et al. Izici ze-Biochemical and pharmacokinetic zokwelashwa ngomlomo nge-chondroitin sulfate. I-Arzneimittelforschung 1995; 45: 918-25. Buka okungaqondakali.
161. URonca F, uPalmieri L, uPanicucci P, et al. Umsebenzi olwa nokuvuvukala we-chondroitin sulfate. I-Osteoarthritis Cartilage 1998; I-6 Suppl A: 14-21. Buka okungaqondakali.
162. U-Andermann G, Dietz M. Umthelela wendlela yokuphatha ekutholakaleni kwe-macromolecule engapheli: i-chondroitin sulphate (CSA). I-Eur J Drug Metab Pharmacokinet 1982; 7: 11-6. Buka okungaqondakali.
163. UConte A, de Bernardi M, Palmieri L, et al. Isiphetho semetabolism ye-chondroitin sulfate engaphandle kumuntu. I-Arzneimittelforschung 1991; 41: 768-72. Buka okungaqondakali.
164. UMcAlindon TE, iLungu lePhalamende laseLaValley, uGulin JP, uFelson DT. I-Glucosamine ne-chondroitin yokwelashwa kwe-osteoarthritis: ukuhlolwa kwekhwalithi okuhlelekile nokuhlaziywa kwe-meta. I-JAMA 2000; 283: 1469-75. Buka okungaqondakali.
165. I-Limberg MB, iMcCaa C, i-Kissling GE, uKaufman HE. Ukusetshenziswa kwezihloko kwe-hyaluronic acid ne-chondroitin sulfate ekwelapheni amehlo omile. Ngingu-J Ophthalmol 1987; 103: 194-7. Buka okungaqondakali.
166. UKelly GS. Indima ye-glucosamine sulphate ne-chondroitin sulfates ekwelapheni izifo ezihlangene eziwohlokayo. I-Altern Med Rev 1998; 3: 27-39. Buka okungaqondakali.
167. I-Bucsi L, i-Poor G. Ukusebenza nokubekezelela i-chondroitin sulfate yomlomo njengesidakamizwa esisebenza ngokuhamba kancane se-osteoarthritis (SYSADOA) ekwelapheni i-knee osteoarthritis. I-Osteoarthritis Cartilage 1998; I-6 Suppl A: 31-6. Buka okungaqondakali.
168. UBourgeois P, uChales G, uDehais J, et al. Ukusebenza nokubekezelela i-chondroitin sulfate 1200 mg / day vs chondroitin sulfate 3 x 400 mg / day vs placebo. I-Osteoarthritis Cartilage 1998; 6: 25-30. Buka okungaqondakali.
169. Uebelhart D, Thonar EJ, Delmas PD, et al. Imiphumela ye-chondroitin sulphate yomlomo ekuqhubekeni kwe-knee osteoarthritis: isifundo somshayeli. I-Osteoarthritis Cartilage 1998; 6: 39-46. Buka okungaqondakali.
170. UMorrison LM, u-Enrick N. Coronary isifo senhliziyo: ukwehliswa kwezinga lokufa yi-chondroitin sulfate A. Angiology 1973; 24: 269-87. Buka okungaqondakali.
171. U-Lewis CJ. Incwadi yokuphinda ukukhathazeka okuthile kwezempilo nokuphepha komphakathi kumafemu akhiqiza noma angenisa izengezo zokudla eziqukethe izicubu ezithile zezinkomo.I-FDA. Itholakala ku-: www.cfsan.fda.gov/~dms/dspltr05.html.
172. ULeeb BF, uSchweitzer H, uMontag K, uSmolen JS. Ukuhlaziywa kwe-meta-chondroitin sulfate ekwelapheni i-osteoarthritis. UJ Rheumatol 2000; 27: 205-11. Buka okungaqondakali.
173. I-Bagasra O, i-Whittle P, i-Heins B, i-Pomerantz RJ. I-anti-human immunodeficiency virus hlobo 1 umsebenzi wama-monosaccharides ane-sulfated: ukuqhathanisa nama-polysaccharides ane-sulfated namanye ama-polyions. J Ukuthelela Dis 1991; 164: 1082-90. Buka okungaqondakali.
174. UJurkiewicz E, uPanse P, uJentsch KD, et al. In vitro anti-HIV-1 umsebenzi we-chondroitin polysulphate. I-AIDS 1989; 3: 423-7. Buka okungaqondakali.
175. UChavez ML. I-Glucosamine sulfate ne-chondroitin sulfates. I-Hosp Pharm 1997; 32: 1275-85.
176. UMazieres B, uLoyau G, uMenkes CJ, et al. [I-Chondroitin sulfate ekwelapheni i-gonarthrosis ne-coxarthrosis. Imiphumela yezinyanga ezi-5 yocwaningo olulawulwayo olunezimpumputhe eziphindwe kabili ezisebenzisa i-placebo]. UMfu Rhum Mal Osteoartic 1992; 59: 466-72. Buka okungaqondakali.
177. I-Conrozier T. [Anti-arthrosis treatment: ukusebenza kahle nokubekezelelana kwama-chondroitin sulfates]. Phakamisa iMed 1998; 27: 1862-5. Buka okungaqondakali.
178. UMorreale P, uManopulo R, uGalati M, et al. Ukuqhathaniswa kokusebenza kokulwa nokuvuvukala kwe-chondroitin sulfate ne-diclofenac sodium ezigulini ezinedolo le-osteoarthritis. UJ Rheumatol 1996; 23: 1385-91. Buka okungaqondakali.

Kugcine ukubuyekezwa - 02/20/2020